Cargando…
Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics
Prostate cancers may reactivate a latent embryonic program called the epithelial–mesenchymal transition (EMT) during the development of metastatic disease. Through EMT, tumors can develop a mesenchymal phenotype similar to cancer stem cell traits that contributes to metastasis and variation in thera...
Autores principales: | Chaves, Luiz Paulo, Melo, Camila Morais, Saggioro, Fabiano Pinto, dos Reis, Rodolfo Borges, Squire, Jeremy Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701270/ https://www.ncbi.nlm.nih.gov/pubmed/34946849 http://dx.doi.org/10.3390/genes12121900 |
Ejemplares similares
-
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer
por: Melo, Camila Morais, et al.
Publicado: (2021) -
Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence
por: Lautert-Dutra, William, et al.
Publicado: (2023) -
Emerging role of PTEN loss in evasion of the immune response to tumours
por: Vidotto, Thiago, et al.
Publicado: (2020) -
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
por: Zhang, Yun, et al.
Publicado: (2018) -
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities
por: Huang, Zhao, et al.
Publicado: (2022)